ANNUAL REPORT 2012 - TiGenix

Date Transaction Number and class
of shares issued
Issuance
price per
share (EUR)
(incl.
issuance
premium)
Capital
increase
(EUR)
Share
capital after
transaction
Aggregate
number
of shares
after capital
increase
PHASE XI CAPITAL ROUND
June 6,
2011
Capital
15,187,111 1.00 14,848,609.05 89,091,655.28 91,122,667
in cash (27)
increase
PHASE XII CONTRIBUTION IN RELATION TO THE ORTHOMIMETICS ACQUISITION
April 17,
2012
Capital
536,534 4.28 525,803.32 89,617,458.60 91,659,201
in kind (28)
increase
PHASE XIII CAPITAL DECREASE
May 11,
2012
Capital
decrease (29)
NA NA Decrease
of EUR
80,451,538.50
9,165,920.10 91,659,201
PHASE XIV CAPITAL ROUND
December
27, 2012
Capital
8,629,385 0.78 862,938.50 10,028,858.60 100,288,586
in cash (30)
increase
Notes
(1)
The shares were subscribed to by Gemma Frisius-Fonds K.U.Leuven NV (85,800 A), Katholieke Universiteit Leuven (14,200 C), Axxis
V&C BVBA (25,000 B) and Prof. Dr. Frank Luyten (25,000 B). At the time of incorporation, also 200,000 profit certificates were issued
to Katholieke Universiteit Leuven (25,000 C), Axxis V&C BVBA (87,500 B) and Prof. Dr. Frank Luyten (87,500 B). These profit certificates
were converted into 200,000 shares on September 15, 2003.
(2)
The shares were subscribed to by Gemma Frisius-Fonds K.U.Leuven NV (364,200 A) and Katholieke Universiteit Leuven (60,800 C).
(3)
The shares were subscribed to by Gemma Frisius-Fonds K.U.Leuven NV (150,000 A), Axxis V&C BVBA (20,000 B) and Prof. Dr. Frank
Luyten (20,000 B), Katholieke Universiteit Leuven (more precisely, its division Universitaire Ziekenhuizen Leuven) (100,000 C), Johan
Bellemans (20,000 D) and Etienne Schacht (10,000 D).
(4)
The shares were subscribed to by ING België NV (1,771,605 E), Capricorn Venture Fund II NV (1,012,346 E) and Fagus NV (1,265,432
E).
(5)
The shares were subscribed to by Gemma Frisius-Fonds K.U.Leuven NV (290,896 A), Katholieke Universiteit Leuven (64,506 C) and
Universiteit Gent (329,600 C).
(6)
The profit certificates were issued on February 21, 2000 and were converted on September 15, 2003 by Katholieke Universiteit
Leuven (25,000 C), Axxis V&C BVBA (87,500 B) and Prof. Dr. Frank Luyten (87,500 B).
(7)
The shares were subscribed to by Auriga Ventures II FCPR (1,518,519 E).
(8)
The shares were subscribed to by ING België NV (432,099 E), Capricorn Venture Fund II NV (246,913 E), Fagus NV (308,642 E) and
Auriga Ventures II FCPR (370,370 E).
(9)
The shares were subscribed to by ING België NV (144,034 E), Capricorn Venture Fund II NV (82,306 E), Fagus NV (102,882 E) and
Auriga Ventures II FCPR (123,458 E).
(10)
The “adjustment” warrants were issued on September 15, 2003 to and exercised in 2005 by Gemma Frisius-Fonds K.U.Leuven NV
(11,762 A), Katholieke Universiteit Leuven (2,608 C) and Universiteit Gent (13,327 C). The “adjustment” warrants were used as an
instrument to adjust the subscription price paid by the warrant holders for new shares issued in September 2003 compared to the
average subscription price paid by other investors who also committed in September 2003 to contribute a fixed amount but in
three instalments at variable subscription prices.
(11)
The warrants were issued on March 22, 2001 and exercised in 2005 by Karel Fol (12,500 D) and Koen Huygens (10,000 D).
Subsequently, 9,000 of these shares were sold by Karel Fol (5,000 D) and Koen Huygens (4,000 D) to Gemma Frisius-Fonds
K.U.Leuven NV and were re-allocated to Class A.
32 TiGenix I annual report 2012